Visceral leishmaniasis
- PMID: 22632641
- DOI: 10.1016/j.idc.2012.03.005
Visceral leishmaniasis
Abstract
Visceral leishmaniasis (VL) is a vector-borne parasitic disease targeting tissue macrophages. It is among the most neglected infectious diseases. Classical manifestations of VL include chronic fever, hepatosplenomegaly, and pancytopenia. Most cases can be detected through serologic and molecular testing. Although therapy has historically relied on antimonials, newer therapeutic options include conventional or liposomal amphotericin B, paromomycin and miltefosine. Coinfection with human immunodeficiency virus (HIV) is increasingly reported and comes with additional diagnostic and therapeutic challenges. This article provides an up-to-date clinical review of VL focusing on clinical presentation, diagnosis, management, and issues related to HIV coinfection.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?Nat Rev Microbiol. 2007 Nov;5(11):873-82. doi: 10.1038/nrmicro1748. Nat Rev Microbiol. 2007. PMID: 17938629 Review.
-
Leishmaniasis: an update of current pharmacotherapy.Expert Opin Pharmacother. 2013 Jan;14(1):53-63. doi: 10.1517/14656566.2013.755515. Epub 2012 Dec 21. Expert Opin Pharmacother. 2013. PMID: 23256501 Review.
-
[Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].Med Mal Infect. 2009 Oct;39(10):741-4. doi: 10.1016/j.medmal.2009.05.001. Epub 2009 Sep 23. Med Mal Infect. 2009. PMID: 19783391 Review. French.
-
Childhood visceral leishmaniasis.Indian J Med Res. 2006 Mar;123(3):353-6. Indian J Med Res. 2006. PMID: 16778316 Review.
-
Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis.Scand J Infect Dis. 2009;41(10):777-81. doi: 10.1080/00365540903104127. Scand J Infect Dis. 2009. PMID: 19593691
Cited by
-
Visceral leishmaniasis and HIV coinfection: time for concerted action.PLoS Negl Trop Dis. 2014 Aug 28;8(8):e3023. doi: 10.1371/journal.pntd.0003023. eCollection 2014 Aug. PLoS Negl Trop Dis. 2014. PMID: 25166269 Free PMC article. No abstract available.
-
Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):679-86. doi: 10.1007/s10096-014-2282-9. Epub 2014 Nov 19. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25407374
-
Case Report: Diagnosis and Treatment of Two Clinical Cases of Visceral Leishmaniasis-Related Hemophagocytic Lymphohistiocytosis.Am J Trop Med Hyg. 2023 Jul 10;109(2):296-300. doi: 10.4269/ajtmh.22-0776. Print 2023 Aug 2. Am J Trop Med Hyg. 2023. PMID: 37429573 Free PMC article.
-
Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Front Immunol. 2018 Jan 12;8:1943. doi: 10.3389/fimmu.2017.01943. eCollection 2017. Front Immunol. 2018. PMID: 29375567 Free PMC article. Review.
-
Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.Sci Rep. 2016 Sep 14;6:33059. doi: 10.1038/srep33059. Sci Rep. 2016. PMID: 27624408 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources